Small-molecule α-CGRP receptor antagonists, gepants, and fully humanized monoclonal antibodies towards CGRP and the α-CGRP receptor showed beneficial effects in reducing migraine symptoms in clinical trials [19,185]. This evidence concerns the gene CALCA and migraine disorder.